

MELAN ACCRUAL REPORT - Open and Recently Closed Studies

SWOG/ Support	STUDY	O R P E E G N	ARM	ACCR. GOAL	TOTAL REGS.	REGS.	REGS.	REGS.	REGS.	REGS.	DATE OF FIRST REG.	# of ACT. INSTs	# of CURR IRBs	
						LAST 12 Month	LAST 6 Month	LAST 3 Month	LAST 30 DAYS	LAST 7 DAYS				
SWOG	S1320-Adv, BRAF mut, Inter v Contin	1	Y 1	Lead-in Continuous Dosing	280	220	54	23	5	1	0	09/19/2014	227	100
						220	54	23	5	1	0			
		2	Y 2	Continuous Dosing	237	94	27	12	5	2	0	09/19/2014		
				3 Intermittent Dosing		90	24	12	4	1	0			
						184	51	24	9	3	0			
	S1512-Melan, Adv, Desmoplastic, MK-3475 (pembro)	1	Y 1	MK-3475 (pembrolizumab)	77	13	10	7	3	1	0	02/06/2017	90	42
						13	10	7	3	1	0			
	S1607-MELAN, Adv, T-VEC, MK-3475	1	Y 1	T-VEC + MK-3475(pembrolizumab)	64	2	2	2	2	0	0	06/05/2018	30	19
						2	2	2	2	0	0			
	S1616-MELAN, Adv, Ipilimumab ± Nivolumab	1	Y 1	Ipilimumab	94	8	8	6	5	1	1	10/23/2017	235	94
				2 Nivolumab + Ipilimumab		14	14	9	7	2	2			
						22	22	15	12	3	3			
Yes	EA6134-Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T	1	E	Total Registrations		27	10	3	1	1	1	11/03/2015	365	156
						27	10	3	1	1	1			
		2	E	Total Registrations		10	6	5	3	3	0	11/03/2015		
						10	6	5	3	3	0			
	EA6141-Melan, Avd, Nivolumab+Ipi ± Sargmostim	1	E	Total Registrations		36	0	0	0	0	0	03/25/2016	306	121
						36	0	0	0	0	0			